ASCO22: practice-changing results for high-dose ifosfamide in the treatment of Ewing sarcoma

Findings from the rEECur study have been presented at the Annual Society of Clinical Oncology (ASCO) Meeting 2022 (3–7 June, IL, USA). The trial is the first to provide comparative toxicity and survival data for the four most common chemotherapy regimens in recurrent and primary refractory Ewing sarcoma. “The rEECur study has, for the first time, accrued randomized data for four widely used chemotherapy regimens and is now accruing data for a fifth regimen. Before the rEECur study, the basis for choosing drugs for patients with relapsed or refractory Ewing sarcoma was weak and lacking randomized trials to inform clinicians...